Similar articles

• Osimertinib after Chemoradiotherapy in Stage III EGFR-Mutated NSCLC.

  Lu S, Kato T, Dong X, Ahn MJ, Quang LV, Soparattanapaisarn N, Inoue T, Wang CL, Huang M, Yang JC, Cobo M, Özgüroğlu M, Casarini I, Khiem DV, Sriuranpong V, Cronemberger E, Takahashi T, Runglodvatana Y, Chen M, Huang X, Grainger E, Ghiorghiu D, van der Gronde T, Ramalingam SS; LAURA Trial Investigators. Lu S, et al. N Engl J Med. 2024 Aug 15;391(7):585-597. doi: 10.1056/NEJMoa2402614. Epub 2024 Jun 2. N Engl J Med. 2024. PMID: 38828946 Clinical Trial.
• LAURA Completes the Osimertinib Treatment Jigsaw Puzzle of EGFR+ NSCLC from Stage IB to IV: Adjuvant Osimertinib Significantly Improves PFS and CNS Progression in Unresectable Stage III EGFR-Mutated NSCLC Compared to Placebo (LAURA, NCT03521154).

  Luo FX, Arter Z, Ou SI, Nagasaka M. Luo FX, et al. Lung Cancer (Auckl). 2025 Apr 25;16:51-55. doi: 10.2147/LCTT.S520833. eCollection 2025. Lung Cancer (Auckl). 2025. PMID: 40313586 Free PMC article.
• Durvalumab for Stage III EGFR-Mutated NSCLC After Definitive Chemoradiotherapy.

  Aredo JV, Mambetsariev I, Hellyer JA, Amini A, Neal JW, Padda SK, McCoach CE, Riess JW, Cabebe EC, Naidoo J, Abuali T, Salgia R, Loo BW Jr, Diehn M, Han SS, Wakelee HA. Aredo JV, et al. J Thorac Oncol. 2021 Jun;16(6):1030-1041. doi: 10.1016/j.jtho.2021.01.1628. Epub 2021 Feb 12. J Thorac Oncol. 2021. PMID: 33588109
• Therapeutic strategies for EGFR-mutated non-small cell lung cancer patients with osimertinib resistance.

  Fu K, Xie F, Wang F, Fu L. Fu K, et al. J Hematol Oncol. 2022 Dec 8;15(1):173. doi: 10.1186/s13045-022-01391-4. J Hematol Oncol. 2022. PMID: 36482474 Free PMC article. Review.
• Efficacy and safety of osimertinib for patients with EGFR-mutated NSCLC: a systematic review and meta-analysis of randomized controlled studies.

  Li L, Huang Q, Sun J, Yan F, Wei W, Li Z, Liu L, Deng J. Li L, et al. Acta Oncol. 2022 Nov;61(11):1347-1353. doi: 10.1080/0284186X.2022.2132116. Epub 2022 Oct 14. Acta Oncol. 2022. PMID: 36240432